Barclays’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $165K | Sell |
105,487
-89,256
| -46% | -$130K | ﹤0.01% | 3805 |
|
|
2025
Q4 | $224K | Buy |
194,743
+162,881
| +511% | +$224K | ﹤0.01% | 4255 |
|
|
2025
Q3 | $43K | Sell |
31,862
-408
| -1% | -$463 | ﹤0.01% | 4802 |
|
|
2025
Q2 | $30.5K | Sell |
32,270
-113,801
| -78% | -$73.7K | ﹤0.01% | 4787 |
|
|
2025
Q1 | $67.3K | Sell |
146,071
-97,245
| -40% | -$61.4K | ﹤0.01% | 4528 |
|
|
2024
Q4 | $180K | Buy |
243,316
+49,443
| +26% | +$59.6K | ﹤0.01% | 4363 |
|
|
2024
Q3 | $304K | Buy |
193,873
+154,436
| +392% | +$275K | ﹤0.01% | 4081 |
|
|
2024
Q2 | $66.3K | Sell |
39,437
-25,182
| -39% | -$45.2K | ﹤0.01% | 4097 |
|
|
2024
Q1 | $155K | Sell |
64,619
-62,397
| -49% | -$134K | ﹤0.01% | 4238 |
|
|
2023
Q4 | $194K | Buy |
127,016
+87,827
| +224% | +$104K | ﹤0.01% | 4433 |
|
|
2023
Q3 | $42.7K | Buy |
39,189
+1,520
| +4% | +$2.67K | ﹤0.01% | 3937 |
|
|
2023
Q2 | $86.3K | Sell |
37,669
-4,627
| -11% | -$12.3K | ﹤0.01% | 3609 |
|
|
2023
Q1 | $103K | Buy |
42,296
+19,936
| +89% | +$45.7K | ﹤0.01% | 4158 |
|
|
2022
Q4 | $42.7K | Buy |
22,360
+18,829
| +533% | +$40.1K | ﹤0.01% | 4604 |
|
|
2022
Q3 | $8K | Sell |
3,531
-71,723
| -95% | -$199K | ﹤0.01% | 4392 |
|
|
2022
Q2 | $140K | Sell |
75,254
-7,983
| -10% | -$15.2K | ﹤0.01% | 3614 |
|
|
2022
Q1 | $175K | Sell |
83,237
-1,733
| -2% | -$4.8K | ﹤0.01% | 3501 |
|
|
2021
Q4 | $335K | Buy |
84,970
+57,223
| +206% | +$278K | ﹤0.01% | 3373 |
|
|
2021
Q3 | $134K | Buy |
27,747
+14,497
| +109% | +$59.5K | ﹤0.01% | 3788 |
|
|
2021
Q2 | $60K | Sell |
13,250
-28,378
| -68% | -$137K | ﹤0.01% | 4056 |
|
|
2021
Q1 | $244K | Buy |
41,628
+28,248
| +211% | +$196K | ﹤0.01% | 3615 |
|
|
2020
Q4 | $46K | Sell |
13,380
-5,779
| -30% | -$11K | ﹤0.01% | 4441 |
|
|
2020
Q3 | $27K | Sell |
19,159
-123,870
| -87% | -$221K | ﹤0.01% | 4838 |
|
|
2020
Q2 | $287K | Buy |
143,029
+72,550
| +103% | +$142K | ﹤0.01% | 3791 |
|
|
2020
Q1 | $138K | Buy |
70,479
+12,375
| +21% | +$36.8K | ﹤0.01% | 4563 |
|
|
2019
Q4 | $241K | Buy |
58,104
+33,100
| +132% | +$127K | ﹤0.01% | 4893 |
|
|
2019
Q3 | $75K | Sell |
25,004
-2,050
| -8% | -$6.35K | ﹤0.01% | 5691 |
|
|
2019
Q2 | $170K | Buy |
27,054
+10,944
| +68% | +$65.5K | ﹤0.01% | 5262 |
|
|
2019
Q1 | $89K | Buy |
16,110
+13,503
| +518% | +$82K | ﹤0.01% | 5451 |
|
|
2018
Q4 | $18K | Sell |
2,607
-20,042
| -88% | -$162K | ﹤0.01% | 5955 |
|
|
2018
Q3 | $241K | Buy |
22,649
+19,485
| +616% | +$223K | ﹤0.01% | 4858 |
|
|
2018
Q2 | $38K | Sell |
3,164
-15,800
| -83% | -$162K | ﹤0.01% | 5807 |
|
|
2018
Q1 | $163K | Sell |
18,964
-39,281
| -67% | -$363K | ﹤0.01% | 4999 |
|
|
2017
Q4 | $575K | Buy |
58,245
+19,874
| +52% | +$206K | ﹤0.01% | 3665 |
|
|
2017
Q3 | $471K | Buy |
38,371
+8,123
| +27% | +$120K | ﹤0.01% | 3692 |
|
|
2017
Q2 | $498K | Buy |
30,248
+17,518
| +138% | +$271K | ﹤0.01% | 3532 |
|
|
2017
Q1 | $183K | Sell |
12,730
-18,084
| -59% | -$268K | ﹤0.01% | 4414 |
|
|
2016
Q4 | $426K | Buy |
30,814
+27,223
| +758% | +$437K | ﹤0.01% | 3513 |
|
|
2016
Q3 | $64K | Sell |
3,591
-59,625
| -94% | -$960K | ﹤0.01% | 4832 |
|
|
2016
Q2 | $907K | Buy |
63,216
+60,159
| +1,968% | +$816K | ﹤0.01% | 2702 |
|
|
2016
Q1 | $34K | Sell |
3,057
-32,929
| -92% | -$345K | ﹤0.01% | 4982 |
|
|
2015
Q4 | $468K | Buy |
35,986
+5,885
| +20% | +$72.4K | ﹤0.01% | 3272 |
|
|
2015
Q3 | $300K | Buy |
30,101
+29,304
| +3,677% | +$320K | ﹤0.01% | 3800 |
|
|
2015
Q2 | $6K | Sell |
797
-4,130
| -84% | -$30.3K | ﹤0.01% | 6355 |
|
|
2015
Q1 | $0 | Sell |
4,927
-1,895
| -28% | -$12.9K | ﹤0.01% | 7174 |
|
|
2014
Q4 | $0 | Sell |
6,822
-2,288
| -25% | -$18.4K | ﹤0.01% | 7460 |
|
|
2014
Q3 | $63K | Sell |
9,110
-8,717
| -49% | -$93.1K | ﹤0.01% | 5683 |
|
|
2014
Q2 | $125K | Buy |
17,827
+6,890
| +63% | +$74K | ﹤0.01% | 5247 |
|
|
2014
Q1 | $77K | Buy |
10,937
+8,615
| +371% | +$110K | ﹤0.01% | 5659 |
|
|
2013
Q4 | $16K | Sell |
2,322
-264
| -10% | -$4.2K | ﹤0.01% | 6821 |
|
|
2013
Q3 | $36K | Sell |
2,586
-119
| -4% | -$2K | ﹤0.01% | 6240 |
|
|
2013
Q2 | $41K | Buy |
+2,705
| New | +$41.1K | ﹤0.01% | 6440 |
|
Other funds holding LXRX
AG
SL
SC
VCM
Barclays's LXRX Position: Q1 2026 in Review
Barclays reduced its Lexicon Pharmaceuticals (LXRX) stake by 46% in Q1 2026, selling an estimated $130K and leaving 105,487 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #3805.
Barclays first reported a position in LXRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $907K in Q2 2016. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.
- Barclays held 105,487 shares of Lexicon Pharmaceuticals worth $165K as of Q1 2026.
- Barclays sold 89,256 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $130K.
- Lexicon Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3805 holding.
- Barclays first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's Lexicon Pharmaceuticals position peaked at $907K in Q2 2016.
- 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.